Jefferies initiated coverage on EDAP TMS SA with a new price target
$EDAP
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Overweight → Neutral | Piper Sandler | |
| 4/4/2025 | $2.00 | Buy → Hold | Jefferies |
| 11/1/2022 | $11.00 | Buy | Jefferies |
| 11/19/2021 | $12.00 → $11.00 | Buy | HC Wainwright & Co. |
EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU ProceduresCompany to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. "Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system placements increasing 167% year o
EDAP to Present at Jefferies Global Healthcare Conference in London Company to Present and Host 1x1 Investor Meetings on Tuesday, November 18th, 2025 AUSTIN, Texas, November 4, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and host 1x1 investor meetings at the upcoming Jefferies Global Healthcare Conference, which is being held November 18-20, 2025, in London, United Kingdom. Date: Tuesday, November 18th Presentation Time: 4:30-4:55 pm GMT Format: Presentation and 1x1 investor meetings
EDAP to Participate in the UBS Global Healthcare Conference Company to Host 1x1 Investor Meetings on Monday, November 10th, 2025 AUSTIN, Texas, October 27, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer, are scheduled to host 1x1 investor meetings at the upcoming UBS Global Healthcare Conference, which is being held November 10-13, 2025, in Palm Beach Gardens, Florida. Date: Monday, November 10th Format: 1x1 investor meetings Location: PGA National Resort Hotel, Palm Beach Gardens, F
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
S-8 - EDAP TMS SA (0001041934) (Filer)
Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral
Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00
Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00
PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors. "We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technology sector. As EDAP continues to grow the market for its leading Focal One robotic HIFU platform, Josh will help shape our strategic vision and ex
PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One global
New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications LYON, France, June 3, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company's European and Middle Eastern commercial leadership. Mr. Desmedt has been appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm has been appointed General Manager for Switzerland and will
EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU ProceduresCompany to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. "Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system placements increasing 167% year o
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference ca
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)